NeuBase Therapeutics (NBSE)
(Delayed Data from NSDQ)
$0.43 USD
0.00 (-0.83%)
Updated Apr 19, 2024 03:57 PM ET
After-Market: $0.41 -0.02 (-4.65%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.43 USD
0.00 (-0.83%)
Updated Apr 19, 2024 03:57 PM ET
After-Market: $0.41 -0.02 (-4.65%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
by Zacks Equity Research
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
What Makes NeuBase (NBSE) a New Strong Buy Stock
by Zacks Equity Research
NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for January 20th
by Zacks Equity Research
NBSE, PRTG and NOMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2022.
New Strong Buy Stocks for January 20th
by Zacks Equity Research
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
by Zacks Equity Research
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
NeuBase (NBSE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
NeuBase (NBSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NeuBase (NBSE) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
New Strong Buy Stocks for May 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: